1,25(OH)2-16ENE-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia
- 30 June 1994
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 18 (6), 453-463
- https://doi.org/10.1016/0145-2126(94)90081-7
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Topical calcipotriol treatment in advanced breast cancerThe Lancet, 1991
- Lymphocyte cell lines from vitamin D-dependent rickets type II show functional defects in the 1α,25-dihydroxyvitamin D3 receptorMolecular and Cellular Endocrinology, 1990
- The Role of the Vitamin D Endocrine System in Health and DiseaseNew England Journal of Medicine, 1989
- 1,25-Dihydroxyvitamin D3 modulates the expression of a lymphokine (granulocyte-macrophage colony-stimulating factor) posttranscriptionally.Journal of Clinical Investigation, 1988
- Synthetic analogues of vitamin D3 with an oxygen atom in the side chain skeleton A trial of the development of vitamin D compounds which exhibit potent differentiation‐inducing activity without inducing hypercalcemiaFEBS Letters, 1987
- Granulocyte-macrophage colony-stimulating factor. Sensitive and receptor-mediated regulation by 1,25-dihydroxyvitamin D3 in normal human peripheral blood lymphocytes.Journal of Clinical Investigation, 1987
- Treatment of myelodysplastic syndrome with 1.25‐dihydroxy‐vitamin D3American Journal of Hematology, 1986
- Synthetic studies of vitamin D analogues. VII Synthesis of 20-oxa-21-norvitamin D3 analogues.CHEMICAL & PHARMACEUTICAL BULLETIN, 1986
- TREATMENT OF ADVANCED MYELODYSPLASTIC SYNDROME WITH ALFACALCIDOLThe Lancet, 1984
- Basic and Clinical Concepts Related to Vitamin D Metabolism and ActionNew England Journal of Medicine, 1977